---
title: "Gilead posts higher profit as HIV sales rise, helped by prevention drugs"
description: "Gilead Sciences reported a 4% increase in HIV drug sales, totaling $5.3 billion in Q3, aided by its new prevention drug Yeztugo, which generated $39 million. The company's profit was $2.43 per share, "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263595703.md"
published_at: "2025-10-30T20:03:30.000Z"
---

# Gilead posts higher profit as HIV sales rise, helped by prevention drugs

> Gilead Sciences reported a 4% increase in HIV drug sales, totaling $5.3 billion in Q3, aided by its new prevention drug Yeztugo, which generated $39 million. The company's profit was $2.43 per share, surpassing Wall Street's expectations. Total revenue rose 3% to $7.77 billion. Gilead also raised its adjusted earnings estimate for the year to a range of $8.05 to $8.25 per share and increased its 2025 product sales expectations to between $28.4 billion and $28.7 billion.

By Deena Beasley

Oct 30 (Reuters) - Gilead Sciences (GILD.O) said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, helping to boost its profit above Wall Street estimates.

Wall Street expected sales of Yeztugo, which has an annual U.S. list price of about $28,000, at $37.5 million, according to LSEG. The drug is a twice-yearly injection approved by U.S. regulators in June to prevent HIV in adults and adolescents at high risk of contracting the deadly infection.

“We are really pleased with the progress of the Yeztugo launch,” Gilead CEO Daniel O’Day said in an interview, noting that 75% of U.S. payers have agreed to cover the drug, and the company expects that to increase to 90% by mid-2026.

CVS Health (CVS.N) , which runs the largest U.S. pharmacy benefit manager, has still not added Yeztugo to its commercial plans, due to issues including the drug’s high cost.

Gilead, based in Foster City, California, reported a quarterly profit of $2.43 per share, compared with $1.00 a year earlier when it took a large impairment charge. Total revenue rose 3% to $7.77 billion, including $400 million from a one-time sale of intellectual property.

The results beat average Wall Street estimates of $2.13 a share on revenue of $7.45 billion.

Gilead said sales in its liver disease portfolio rose 12% to $819 million, while sales of COVID-19 treatment Veklury fell 60% to $277 million due to lower rates of COVID-related hospitalizations.

Sales of cell therapy products decreased 11% to $432 million, reflecting more competition, while sales of cancer drug Trodelvy rose 7% to $357 million.

For the full year, Gilead raised the lower end of its adjusted earnings estimate by 10 cents to $8.05 per share, but left the top end unchanged at $8.25.

The company also bumped up the low end of its expectations for 2025 product sales to $28.4 billion from $28.3 billion, while the upper end of the range was unchanged at $28.7 billion.

### Related Stocks

- [GILD.US - Gilead Sciences](https://longbridge.com/en/quote/GILD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 吉利德科學｜8-K：2025 財年 Q4 營收 79.25 億美元超過預期 |  | [Link](https://longbridge.com/en/news/275510281.md) |
| 津巴布韋推出新型 HIV 預防藥物 lenacapavir | 津巴布韋推出了長效 HIV 預防藥物 lenacapavir，目標是覆蓋超過 46,000 名高風險個體，分佈在 24 個地點。該項目由美國和全球基金資助，分階段進行，衞生部長道格拉斯·蒙貝肖拉強調了其在抗擊 HIV 中的重要性。lenac | [Link](https://longbridge.com/en/news/276333424.md) |
| 吉利德科學預計 2026 年 HIV 藥物銷售將增長 6%，Yeztugo 的銷售目標為 8 億美元 | 吉利德預計其 2026 年的 HIV 銷售將增長 6%，這得益於最近推出的預防藥物 Yeztugo，預計銷售額將達到 8 億美元，比 2025 年增長 433%。儘管政策變化帶來了一些挑戰，分析師認為這一目標是可以實現的。吉利德 2025  | [Link](https://longbridge.com/en/news/275608247.md) |
| 摩根大通 26：HIV 研發管線的劑量選擇性為吉利德科學提供了優勢 | 在 2026 年摩根大通醫療會議上，吉利德的首席執行官丹尼爾·奧戴強調了公司在 HIV 治療方面的競爭優勢，擁有七款在研藥物。吉利德的產品包括多種治療和預防的給藥選擇，例如最近推出的 Yeztugo，該產品在 2025 年的銷售額達到了 1 | [Link](https://longbridge.com/en/news/272413656.md) |
| 瑞銀和花旗銀行對吉利德科學（GILD）持樂觀態度 | 瑞銀和花旗的分析師對吉利德科學公司（NASDAQ:GILD）表達了樂觀的情緒，認為其是最被低估的藍籌股之一。2026 年 1 月 7 日的報告顯示，市場對吉利德短期和中期前景的信心正在增強，特別是由於對其 HIV 業務的樂觀預期。瑞銀分析師 | [Link](https://longbridge.com/en/news/272248861.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
